Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexketoprofen + morphine is a combination therapy used for the management of moderate to severe acute pain, particularly in postoperative settings. Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that acts as an inhibitor of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects. Morphine is an opioid analgesic that primarily acts as an agonist at the mu-opioid receptor, leading to potent pain relief through central nervous system mechanisms. The combination leverages multimodal analgesia by targeting different pain pathways—peripheral inflammation via dexketoprofen and central nociception via morphine—which can result in synergistic or additive effects on pain control. Clinical studies have shown that using dexketoprofen with morphine reduces overall opioid consumption while maintaining effective analgesia after major surgeries[1][2][5]. This approach aims to enhance pain relief while minimizing opioid-related side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexketoprofen + morphine.